Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Section 6 of 6

References

206 sources

  1. Alban et al. (2025) (opens in a new tab)
  2. Alfaar et al. (2025) (opens in a new tab)
  3. Algazi et al. (2016) (opens in a new tab)
  4. American Cancer Society eye cancer survival rates (2025) (opens in a new tab)
  5. American Cancer Society key statistics for eye cancer (2026) (opens in a new tab)
  6. Atkinson et al. (2017) (opens in a new tab)
  7. Bakalian et al. (2008) (opens in a new tab)
  8. Barbor (2026) (opens in a new tab)
  9. Bauer et al. (2022) (opens in a new tab)
  10. Bedikian et al. (2003) (opens in a new tab)
  11. BioSpace (2026) (opens in a new tab)
  12. Bristol-Myers Squibb OPDIVO prescribing information (2026) (opens in a new tab)
  13. Bristol-Myers Squibb OPDUALAG prescribing information (2026) (opens in a new tab)
  14. Bristol-Myers Squibb YERVOY prescribing information (2026) (opens in a new tab)
  15. Brown et al. (2022) (opens in a new tab)
  16. Brown et al. (2023) (opens in a new tab)
  17. Buder et al. (2013) (opens in a new tab)
  18. CADTH pharmacoeconomic review, tebentafusp (2023) (opens in a new tab)
  19. CADTH rapid response report, radioembolization for uveal melanoma liver metastases (2018) (opens in a new tab)
  20. CADTH reimbursement recommendation, tebentafusp (2023) (opens in a new tab)
  21. Campbell et al. (2026) (opens in a new tab)
  22. Carvajal et al. (2014) (opens in a new tab)
  23. Carvajal et al. (2018) (opens in a new tab)
  24. Carvajal et al. (2022) (opens in a new tab)
  25. Carvajal et al. (2023) (opens in a new tab)
  26. Castle Biosciences Form 10-K (2026) (opens in a new tab)
  27. Chen et al. (2014) (opens in a new tab)
  28. Cheng et al. (2017) (opens in a new tab)
  29. ClinicalTrials.gov NCT02601378 (opens in a new tab)
  30. ClinicalTrials.gov NCT03070392 API record (opens in a new tab)
  31. ClinicalTrials.gov NCT03947385 (opens in a new tab)
  32. ClinicalTrials.gov NCT05987332 (opens in a new tab)
  33. ClinicalTrials.gov NCT05987332 version 1 (opens in a new tab)
  34. ClinicalTrials.gov NCT05987332 version 39 (opens in a new tab)
  35. ClinicalTrials.gov NCT06581406 (opens in a new tab)
  36. CMS Local Coverage Determination L37130, MolDX: DecisionDx-UM (2025) (opens in a new tab)
  37. CMS Quality ID 509 measure specification (2025) (opens in a new tab)
  38. Collaborative Ocular Melanoma Study Group (2001) (opens in a new tab)
  39. Damato et al. (2012) (opens in a new tab)
  40. de Melo et al. (2024) (opens in a new tab)
  41. Delcath HEPZATO KIT prescribing information (2023) (opens in a new tab)
  42. Delcath Systems Form 10-K (2026) (opens in a new tab)
  43. Diener-West et al. (2004) (opens in a new tab)
  44. Diener-West et al. (2005) (opens in a new tab)
  45. Dimitriou et al. (2025) (opens in a new tab)
  46. Eleuteri et al. (2021) (opens in a new tab)
  47. Ellis et al. (2000) (opens in a new tab)
  48. EMA orphan designation EU/3/25/3122 (2025) (opens in a new tab)
  49. Eskelin et al. (1999) (opens in a new tab)
  50. Eskelin et al. (2002) (opens in a new tab)
  51. EU CTIS 2023-506686-66-01 (opens in a new tab)
  52. European Medicines Agency KIMMTRAK orphan maintenance assessment report (2022) (opens in a new tab)
  53. FDA draft guidance on accelerated approval of oncology therapeutics (2023) (opens in a new tab)
  54. FDA guidance page, accelerated approval of oncology therapeutics (2023) (opens in a new tab)
  55. FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018) (opens in a new tab)
  56. FDA Orphan Drug Designations and Approvals (2022) (opens in a new tab)
  57. FDA SeCore CDx HLA Sequencing System De Novo decision summary (2022) (opens in a new tab)
  58. FDA UNII record E0YF0M8O09 (opens in a new tab)
  59. G-BA resolution, tebentafusp reassessment D-995 (2024) (opens in a new tab)
  60. García-Mulero et al. (2023) (opens in a new tab)
  61. Gardner et al. (2014) (opens in a new tab)
  62. Garg et al. (2022) (opens in a new tab)
  63. Gonsalves et al. (2019) (opens in a new tab)
  64. Harbour et al. (2010) (opens in a new tab)
  65. HAS Transparency Committee opinion, KIMMTRAK (2023) (opens in a new tab)
  66. Hassel et al. (2023a) (opens in a new tab)
  67. Hassel et al. (2023b) (opens in a new tab)
  68. Haystack Project press release, uveal melanoma Patient Oriented Value report (2022) (opens in a new tab)
  69. Heppt et al. (2017) (opens in a new tab)
  70. Heppt et al. (2019) (opens in a new tab)
  71. Hikma Dacarbazine for Injection prescribing information (2020) (opens in a new tab)
  72. Honoré et al. (2026) (opens in a new tab)
  73. Hu et al. (2005) (opens in a new tab)
  74. Hughes et al. (2016) (opens in a new tab)
  75. IDEAYA Biosciences clinical trials and expanded access policy (opens in a new tab)
  76. IDEAYA Biosciences corporate presentation, November 2026 (2026) (opens in a new tab)
  77. IDEAYA Biosciences Form 10-K (2025) (opens in a new tab)
  78. IDEAYA Biosciences Form 10-K (2026) (opens in a new tab)
  79. IDEAYA Biosciences Form 10-Q, first quarter 2026 (2026) (opens in a new tab)
  80. IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
  81. IDEAYA Biosciences Form 8-K, Servier license agreement (2025) (opens in a new tab)
  82. IDEAYA Biosciences press release, 2026 corporate objectives (2026) (opens in a new tab)
  83. IDEAYA Biosciences press release, End-of-Phase 1 meeting with FDA (2019) (opens in a new tab)
  84. IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023) (opens in a new tab)
  85. IDEAYA Biosciences press release, ESMO 2026 data (2026) (opens in a new tab)
  86. IDEAYA Biosciences press release, Fast Track designation (2022) (opens in a new tab)
  87. IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023) (opens in a new tab)
  88. IDEAYA Biosciences press release, first quarter 2026 results (2026) (opens in a new tab)
  89. IDEAYA Biosciences press release, first-line OptimUM-01 overall survival at SMR 2025 (2025) (opens in a new tab)
  90. IDEAYA Biosciences press release, fourth quarter and full year 2025 results (2026) (opens in a new tab)
  91. IDEAYA Biosciences press release, IDMC move-forward dose recommendation (2024) (opens in a new tab)
  92. IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026) (opens in a new tab)
  93. IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025) (opens in a new tab)
  94. IDEAYA Biosciences press release, OptimUM-02 topline results (2026) (opens in a new tab)
  95. IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026) (opens in a new tab)
  96. IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021) (opens in a new tab)
  97. IDEAYA Biosciences press release, Real-Time Oncology Review (2026) (opens in a new tab)
  98. IDEAYA Biosciences press release, second quarter 2026 results (2026) (opens in a new tab)
  99. IDEAYA Biosciences press release, third quarter 2026 results (2026) (opens in a new tab)
  100. IDEAYA Biosciences press release, updated OptimUM-02 topline guidance (2026) (opens in a new tab)
  101. Immunocore Form 10-K (2026) (opens in a new tab)
  102. Immunocore KIMMTRAK prescribing information (2024) (opens in a new tab)
  103. Immunocore KIMMTRAK price change notice (2026) (opens in a new tab)
  104. Jager et al. (2020) (opens in a new tab)
  105. Jochems et al. (2019) (opens in a new tab)
  106. Johansson et al. (2016) (opens in a new tab)
  107. Johnson et al. (2019) (opens in a new tab)
  108. Joseph et al. (2026) (opens in a new tab)
  109. Kentucky Department for Medicaid Services clinical diagnostic laboratory fee schedule (2026) (opens in a new tab)
  110. Khoja et al. (2019) (opens in a new tab)
  111. Kim et al. (2010) (opens in a new tab)
  112. Koumprentziotis et al. (2026) (opens in a new tab)
  113. Kujala et al. (2003) (opens in a new tab)
  114. Labcorp test 167107, HLA A A*02:01-Specific (opens in a new tab)
  115. Lane et al. (2018) (opens in a new tab)
  116. Lanzafame et al. (2026) (opens in a new tab)
  117. Leyvraz et al. (2014) (opens in a new tab)
  118. Liu et al. (2026) (opens in a new tab)
  119. Luckett et al. (2025) (opens in a new tab)
  120. Luke et al. (2020) (opens in a new tab)
  121. Luo et al. (2023) (opens in a new tab)
  122. Mahendraraj et al. (2017) (opens in a new tab)
  123. Maio et al. (2013) (opens in a new tab)
  124. Mariani et al. (2009) (opens in a new tab)
  125. McKean et al. (2023) (opens in a new tab)
  126. McKean et al. (2025) (opens in a new tab)
  127. McKean et al. (2026a) (opens in a new tab)
  128. McKean et al. (2026b) (opens in a new tab)
  129. MedlinePlus crizotinib drug information (2022) (opens in a new tab)
  130. Melia et al. (2001) (opens in a new tab)
  131. Merck KEYTRUDA cost information (2026) (opens in a new tab)
  132. Merck KEYTRUDA prescribing information (2026) (opens in a new tab)
  133. Moore et al. (2016) (opens in a new tab)
  134. Najjar et al. (2020) (opens in a new tab)
  135. Nathan et al. (2021) (opens in a new tab)
  136. National Cancer Institute intraocular melanoma treatment PDQ (2025) (opens in a new tab)
  137. National Comprehensive Cancer Network Uveal Melanoma guideline (opens in a new tab)
  138. NCI Drug Dictionary (opens in a new tab)
  139. Ng et al. (2024) (opens in a new tab)
  140. NHS England evidence summary, chemosaturation for liver metastases from ocular melanoma (2015) (opens in a new tab)
  141. NICE resource impact summary report, tebentafusp (2025) (opens in a new tab)
  142. NICE technology appraisal guidance TA1027, committee discussion (2025) (opens in a new tab)
  143. NICE technology appraisal guidance TA1027, information about tebentafusp (2025) (opens in a new tab)
  144. NICE technology appraisal guidance TA1027, recommendations (2025) (opens in a new tab)
  145. Ocumel Canada survey report, the ocular melanoma landscape in Canada (2021) (opens in a new tab)
  146. Olofsson Bagge et al. (2023) (opens in a new tab)
  147. Olofsson Bagge et al. (2025) (opens in a new tab)
  148. OncLive (2026) (opens in a new tab)
  149. Onken et al. (2012) (opens in a new tab)
  150. Orloff et al. (2026a) (opens in a new tab)
  151. Orloff et al. (2026b) (opens in a new tab)
  152. Ott et al. (2026a) (opens in a new tab)
  153. Ott et al. (2026b) (opens in a new tab)
  154. Pelster et al. (2021) (opens in a new tab)
  155. Pfizer XALKORI Connecticut price disclosure (2026) (opens in a new tab)
  156. Pfizer XALKORI prescribing information (2023) (opens in a new tab)
  157. Pham et al. (2023) (opens in a new tab)
  158. Piperno-Neumann et al. (2016) (opens in a new tab)
  159. Piperno-Neumann et al. (2020) (opens in a new tab)
  160. Piperno-Neumann et al. (2023) (opens in a new tab)
  161. Piperno-Neumann et al. (2025) (opens in a new tab)
  162. Piperno-Neumann et al. (2026a) (opens in a new tab)
  163. Piperno-Neumann et al. (2026b) (opens in a new tab)
  164. Piperno-Neumann et al. (2026c) (opens in a new tab)
  165. Piulats et al. (2021) (opens in a new tab)
  166. Piulats et al. (2024) (opens in a new tab)
  167. Radivoyevitch et al. (2021) (opens in a new tab)
  168. Rantala et al. (2019) (opens in a new tab)
  169. Rantala et al. (2021) (opens in a new tab)
  170. Rantala et al. (2022) (opens in a new tab)
  171. Resnick (2026) (opens in a new tab)
  172. Ribeiro et al. (2023) (opens in a new tab)
  173. Robertson et al. (2017) (opens in a new tab)
  174. Rodrigues et al. (2018) (opens in a new tab)
  175. Rodrigues et al. (2025) (opens in a new tab)
  176. Rola et al. (2022) (opens in a new tab)
  177. Rossi et al. (2019) (opens in a new tab)
  178. Roth et al. (2024) (opens in a new tab)
  179. Rowcroft et al. (2020) (opens in a new tab)
  180. Sacco et al. (2024a) (opens in a new tab)
  181. Sacco et al. (2024b) (opens in a new tab)
  182. Salama et al. (2026) (opens in a new tab)
  183. Sato et al. (2025) (opens in a new tab)
  184. Schinzari et al. (2017) (opens in a new tab)
  185. Schuermeyer et al. (2016) (opens in a new tab)
  186. Scottish Medicines Consortium advice SMC2910, tebentafusp (2026) (opens in a new tab)
  187. Shoushtari et al. (2021) (opens in a new tab)
  188. Siegel et al. (2026) (opens in a new tab)
  189. Steckler et al. (2022) (opens in a new tab)
  190. Steeb et al. (2018) (opens in a new tab)
  191. Tong et al. (2024) (opens in a new tab)
  192. Valsecchi et al. (2015) (opens in a new tab)
  193. van den Hoek et al. (2026) (opens in a new tab)
  194. van der Kooij et al. (2025) (opens in a new tab)
  195. Van Raamsdonk et al. (2010) (opens in a new tab)
  196. Vigneswaran et al. (2024) (opens in a new tab)
  197. Visser et al. (2024) (opens in a new tab)
  198. Wagle et al. (2021) (opens in a new tab)
  199. Wei et al. (2022) (opens in a new tab)
  200. Weinberger et al. (2025) (opens in a new tab)
  201. WHO Collaborating Centre ATC/DDD Index (2026) (opens in a new tab)
  202. Xu et al. (2019) (opens in a new tab)
  203. Yamada et al. (2024) (opens in a new tab)
  204. Zager et al. (2024) (opens in a new tab)
  205. Zager et al. (2025) (opens in a new tab)
  206. Zimmer et al. (2015) (opens in a new tab)